Skip to main content

          -  U.S. Department of Health & Human Services 

            - Virtual Tour
            - Staff Directory
            - En Español

## Site Menu

-  Home 
-  Health Information  - Health Care Providers & Facilities
- Health Info Lines
- HealthCare.gov
- Science Education Resources
- NIH Clinical Research Trials and You
- Talking to Your Doctor

More »

Search Health Topics

Quick Links
- MedlinePlus Health Info
- NIH News in Health
- Wellness Toolkits
 
-  Grants & Funding  - Grants Home Page
- Find Funding
- Due Dates
- How to Apply
- About Grants
- Policy & Compliance
- Grants News/Blog
- Contracts
- Loan Repayment

More »

Quick Links
- RePORT
- eRA Commons
- NIH Common Fund
 
-  News & Events  - News Releases
- Digital Media Kits
- Media Resources
- Media Contacts
- Images and B-roll
- Events
- Social Media

More »

Quick Links
- NIH News in Health
- NIH Research Matters
- NIH Record
 
-  Research & Training  - Medical Research Initiatives
- Science Highlights
- Science Education
- Research in NIH Labs & Clinics
- Training Opportunities
- Library Resources
- Research Resources
- Clinical Research Resources
- Safety, Regulation and Guidance

More »

Quick Links
- PubMed
- Stem Cell Information
- OppNet
- NIDB
- NIH Blueprint for Neuroscience Research
 
-  Institutes at NIH  - List of Institutes and Centers
- NIH Office of the Director
- Directors of NIH Institutes and Centers
- NIH Institute and Center Contact Information

More »

Quick Links
- NCI
- NEI
- NHLBI
- NHGRI
- NIA
- NIAAA
- NIAID
- NIAMS
- NIBIB
- NICHD
- NIDCD
- NIDCR
- NIDDK
- NIDA
- NIEHS
- NIGMS
- NIMH
- NIMHD
- NINDS
- NINR
- NLM
- CC
- CIT
- CSR
- FIC
- NCATS
- NCCIH
 
-  About NIH  - Who We Are
- What We Do
- Jobs at NIH
- Visitor Information
- Frequently Asked Questions
- Contact Us

More »

Quick Links
- The NIH Director
- Take the Virtual Tour
- NIH…Turning Discovery Into Health®
- Impact of NIH Research
- Science, Health, and Public Trust
 

## You are here

HomeNews & EventsNews Releases

## News Releases

Media Advisory

Wednesday, April 3, 2024

# Drug shows promise for slowing progression of rare, painful genetic disease

NIH-supported clinical trial could lead to first effective treatment for ACDC disease.

A CT angiography scan of a person with ACDC disease showing abnormal calcification of the blood vessels in the legs and feet. NHLBI

### What

A drug used to treat certain bone diseases shows promise for slowing the progression of a rare, painful genetic condition that causes excessive calcium buildup in the arteries, known as arterial calcification due to deficiency of CD73 (ACDC). These results are from a first-in-human clinical trial supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. The study, published in the journal *Vascular Medicine*, could lead to the first effective treatment for the rare disease.

ACDC, which has no known cure, often targets the arteries of the legs and can make walking painful and difficult. It can also affect the joints of the hands, causing pain and deformities. In severe cases, the condition can lead to potential limb loss. Symptoms of the disease often begin in the late teens and 20s. An extremely rare disease, it is believed to affect only about 20 people worldwide and has an estimated prevalence of less than 1 in 1 million. Previous studies have identified the gene for ACDC disease and the biochemical mechanism behind it. More recent studies by the NHLBI research team identified an existing drug, called etidronate, as a potential treatment for ACDC based on disease models in animals and human cells.

In the study, researchers evaluated the safety and effectiveness of etidronate in treating calcification of the arteries and impaired blood flow in the legs of seven people (four women and three men) with ACDC disease. Although few, they collectively represent about one-third of all the known cases in the world. Treatment consisted of taking the oral drug daily for 14 days every three months over a three-year period. The researchers measured calcium deposits using CT scans and tested blood flow using the ankle brachial index, a non-invasive tool, both at the start of the study and as a yearly follow-up after treatment.	Researchers found that etidronate treatments appeared safe, with no adverse side effects reported. The drug appeared to slow the progression of new calcium deposits in the blood vessels of the legs as well as slow the progression of blood flow inhibition. However, the drug did not reverse calcium deposits that were already present in the affected blood vessels and joints, nor did it show clear improvement in blood flow. Questionnaires administered to the patients suggested that symptoms, such as pain and motion impairment, were improved.

Researchers suggest that lessons learned from the current study could allow development of novel therapies for ACDC and larger clinical trials for this disease. The study could also shed light on other diseases involving excessive calcium buildup in the arteries, including peripheral artery disease and atherosclerosis.

### Reference

Ferrante EA, Cudrici CD, Rashidi M, et al. Pilot study to evaluate the safety and effectiveness of etidronate treatment for arterial calcification due to deficiency of CD73 (ACDC). Vascular Medicine. 2024. doi: 10.1177/1358863X241235669

### Who

Elisa Ferrante, Ph.D., clinical program manager and staff scientist in the Translational Vascular Medicine Branch at NHLBI, and Alessandra Brofferio, M.D., clinical cardiologist with the Laboratory of Cardiovascular Regenerative Medicine of NHLBI.

**About the National Heart, Lung, and Blood Institute (NHLBI):** NHLBI is the global leader in conducting and supporting research in heart, lung, and blood diseases and sleep disorders that advances scientific knowledge, improves public health, and saves lives. For more information, visit www.nhlbi.nih.gov.

**About the National Institutes of Health (NIH):**NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

*NIH…Turning Discovery Into Health®*

###

### Institute/Center

National Heart, Lung, and Blood Institute (NHLBI)

### Contact

NHLBI Engagement and Media Relations Branch

### Connect with Us

                      - Subscribe to news releases
                      - RSS Feed

## Connect with Us

                  - Contact Us
                  - X
                  - Facebook
                  - Instagram
                  - YouTube
                  - Flickr
                  - More Social Media from NIH

## Footer

- NIH Home
- Virtual Tour
- En Español
- Visitor Information
- Frequently Asked Questions
- Privacy Policy
- Disclaimers
- Accessibility
- NIH Website Archives

- Nondiscrimination Notice
- Freedom of Information Act
- No Fear Act
- HHS Vulnerability Disclosure
- Office of Inspector General
- USA.gov

NIH…Turning Discovery Into Health®

National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892

U.S. Department of Health and Human Services

Back to Top